Teva's generic Risperdal cleared in USA

19 September 2013

The US Food and Drug Administration has approved world generics giant Teva Pharmaceutical Industries' Abbreviated New Drug Application to market its generic version of Risperdal (risperidone) oral solution, 1mg/mL.

The product is part of a blockbuster antipsychotic franchise developed by US health care major Johnson & Johnson. Shipment of the generic has already commenced, Teva noted.

The brand product had annual sales of approximately $78.0 million in the USA for the 12 months that ended September 30, 2008, based on IMS sales data.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK